Statement: The Single IV Infusion of ZA 4 mg group of the primary trial had a smaller Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen than the Odanacatib 5 mg group
Primary_evidence: Outcome Measurement:    Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen (u-NTx) at Week 4   u-NTx is a biochemical index of bone resorption. Participants provided urine specimens on Day 1 (baseline) and at Week 4 for measurement of u-NTx.   Time frame: Baseline and Week 4 Results 1:    Arm/Group Title: Single IV Infusion of ZA 4 mg   Arm/Group Description: Participants received a single IV infusion of ZA 4 mg at the start of treatment and a once-daily odanacatib matching placebo tablet for 4 weeks.   Overall Number of Participants Analyzed: 14   Mean (95% Confidence Interval)   Unit of Measure: Percentage change  -73        (-80 to -62) Results 2:    Arm/Group Title: Once-daily Odanacatib 5 mg   Arm/Group Description: Participants received a once-daily odanacatib 5 mg tablet for 4 weeks and a single IV infusion of ZA matching placebo at the start of treatment.   Overall Number of Participants Analyzed: 27   Mean (95% Confidence Interval)   Unit of Measure: Percentage change  -77        (-82 to -71)